SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Peter Thompson, president, chief executive officer and chairman of Trubion, is scheduled to present a corporate update at the upcoming Lazard Capital Markets Healthcare Investor Conference to be held at The New York Palace Hotel. Dr. Thompson is scheduled to present Nov. 27, 2007, at 2:30 p.m. Interested parties may access the live audio webcast of the presentation by visiting the Wall Street Webcasting link at http://www.wsw.com/webcast/lz4/trbn.
Trubion is a biopharmaceutical company creating a pipeline of product
candidates to treat autoimmune disease and cancer. The company's product
candidates are novel proteins known as single-chain polypeptides and are
designed using its SMIP(TM) custom drug assembly technology. In less than
24 months, the company designed, developed and submitted to the FDA an
Investigational New Drug (IND) application for its lead product candidate,
TRU-015, which has completed a Phase IIb clinical trial for the treatment
of rheumatoid arthritis. In December 2005, the company entered into a
collaboration agreement with Wyeth for the development and worldwide
commercialization of certain therapeutics, including TRU-015. In addition,
Trubion's TRU-016 program targets CD37, an antigen present on B cells, for
the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion
currently retains all development and commercialization rights for the
TRU-016 program. For additional information, visit http://www.trubion.com.
Senior Director, Corporate Communications
Trubion Pharmaceuticals Inc.
Senior Vice President
Waggener Edstrom Healthcare
|SOURCE Trubion Pharmaceuticals Inc.|
Copyright©2007 PR Newswire.
All rights reserved